| Synonym |
| Thai / English name |
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : -Type of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : Non-specifiedInteraction with drug : BitolterolDose/Conc.(drug) : -Result : PositiveRemark :Note : - Ginkgo biloba leaf extraction including Ginkgo biloba flavonoids and/or ginkgolides and Beta-adrenoceptor agonist including one or more of salmeterol, formoterol, salbutamol, clenbuterol, terbutaline, fenoterol, mabuterol, procaterol, orciprenaline, tulobuterol, bitolterol and fenspiride. - Ginkgo biloba leaf extraction and Beta-adrenoceptor agonist have synergic effect, which is significant for treating respiratory diseases. - Data incomplete.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : -Type of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : Non-specifiedInteraction with drug : FenspirideDose/Conc.(drug) : -Result : PositiveRemark :Note : - Ginkgo biloba leaf extraction including Ginkgo biloba flavonoids and/or ginkgolides and Beta-adrenoceptor agonist including one or more of salmeterol, formoterol, salbutamol, clenbuterol, terbutaline, fenoterol, mabuterol, procaterol, orciprenaline, tulobuterol, bitolterol and fenspiride. - Ginkgo biloba leaf extraction and Beta-adrenoceptor agonist have synergic effect, which is significant for treating respiratory diseases. - Data incomplete.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Natural standardized extraction of Ginkgo biloba leaves (Gin, Egb 761)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : *Duration : 2 weeksType of interaction : PharmacodynamicsInteraction with drug : AprotininDose/Conc.(drug) : -Result : PositiveRemark : Aprotinin alone significantly reduced the venom-elicited increase in glucose-6-phosphate dehydrogenase and lactate dehydrogenase activities and decrease in glutathione peroxidase levels (p<0.05). In general, these protective effects of EGb 761 on reduced glutathione, malondialdehyde (p<0.01 vs. venom) and lactate dehydrogenase (p< 0.001) in the heart/or lung were potentiated when combined with aprotinin.Note : * Rats were treated with leiurus quinquestriatus (LQQ) venom (0.3 mg/kg, s.c.) alone or after Gin (150 mk/kg, orally, daily for 2 weeks before venom) and/or aprotinin (Apr, 46000 KIU/kg, i.p., 30 min before venom). Control groups were injected with saline or treatment modalities. - Data incomplete.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Ginkgo biloba special extraction (EGb 761)Type of experiment : humanType of animal : -Type of study : Double-blind trialN(Total) : 50N(Treatment) : 50Sex : MaleAge : 20-44 yearsRoute : Oral administrationDose/Conc.(herb) : *Duration : **Type of interaction : PharmacodynamicsInteraction with drug : Aspirin*/Acetylsalicylic acid/ASA/EcosprinDose/Conc.(drug) : -Result : EquivocalRemark : Results: Acetylsalicylic acid (ASA) and the combination of ASA +EGb 761 exerted quite similar effects on all coagulation parameters measured, including bleeding time (ASA alone: 4.1 min before therapy, 6.2 min after therapy; ASA + EGb 761: 4.2 min before therapy, 6.3 min after therapy; ratio of means 1.01, 90% Cl 0.86, 1.19) and agonist - induced platelet aggregation (collagen - induced platelet aggregation - ASA: 84.5% before therapy, 81.0% after therapy; ASA + EGb 761: 86.6% before therapy, 81.0% after therapy; ratio of means: 1.00, 90% Cl 0.95, 1.05; ADP-induced platelet aggregation -ASA: 72.6% before therapy, 47.2% after therapy; ASA + EGb 761: 71.7% before therapy, 44.8% after therapy; ratio of means: 0.95, 90% Cl 0.85, 1.06).Note : *Dose: Study medication was taken twice daily (ASA group: ASA 500 mg tablet + placebo - coated tablate in the morning and placebo tablet + placebo - coated tablet in evening; ASA + EGb 761 group: ASA 500 mg tablet + EGb 761 120 mg - coated tablet in the morning and placebo tablet + EGb 761 120 mg - coated tablet in evening. **Duration: Each treatment lasted 7 days, the washout period between treatment was 3 weeks. - Data incomplete.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Ginkgo biloba extraction (GBE)Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10N(Treatment) : 10Sex : MaleAge : -Route : Oral administrationDose/Conc.(herb) : GBE intake 360 mg/dDuration : 28 daysType of interaction : PharmacokineticsInteraction with drug : TolbutamideDose/Conc.(drug) : -Result : PositiveRemark : - Tolbutamide 125 mg were orally administered to 10 male healthy volunteers before and after GBE intake, and received 75 g glucose after the dosing of tolbutamide. - The area under concentration vs. time curve (AUC0-alpha) for tolbutamide after GBE intake was slightly but significantly (16%) lower than that before GBE intake. Concomitantly, GBE tended to attenuate AUC0-2 of blood glucose-lowering effect of tolbutamide.Note : - Data incomplete
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Ginkgo biloba extraction (GBE)Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10N(Treatment) : 10Sex : MaleAge : -Route : Oral administrationDose/Conc.(herb) : GBE intake 360 mg/dDuration : 28 daysType of interaction : PharmacokineticsInteraction with drug : Midazolam*/Versed/DormicumDose/Conc.(drug) : -Result : PositiveRemark : - Midazolam 8 mg were orally administered to 10 male healthy volunteers before and after GBE intake. - AUC0-alpha for midazolam was singnificantly (25%) increased by GBE intake and oral clearance was significantly (26%) decreased.Note : - Data incomplete
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 86N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : Ginkgo leaves tablets 19.2 mg three times one dayDuration : one dayType of interaction : PharmacodynamicsInteraction with drug : ParoxetineDose/Conc.(drug) : -Result : PositiveRemark : The therapeutic effect of the Ginkgo leaves tablets and paroxetine treatment is better than using paroxetine only in the treatment of depression can ameliorate depression and correlated body symptom efficiently and toleration is good.Note : - The 86 depression patients, who visited psycho clinic in Tang Du Hospital, are selected, and they are numbered by the order of visiting and diagnosing, the single numbers are study group (the Ginkgo leaves tablets and Paroxetine) and the even numbers are ontrol group (only Paroxetine). The two groups are all treated with Paroxetine, the dosage is 20 mg, once in the morning daily. Ginkgo leaves tablets 19.2 mg are also taken three time one day by the patients in the study group. They are treated and observed for 6 weeks, evaluated by HAMD. - Data incomplete.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Extract of folium ginkgoType of experiment : humanType of animal : -Type of study : Open trialN(Total) : 35N(Treatment) : 18Sex : -Age : childrenRoute : Oral administrationDose/Conc.(herb) : -Duration : -Type of interaction : PharmacodynamicsInteraction with drug : Prednisone*/Deltacortisone/DeltdehydrocortisoneDose/Conc.(drug) : -Result : PositiveRemark :Note : - Thirty-five children with nephrotic syndrome were randomized into two group treated with prednisone plus extract of Folium Ginkgo (therapeutic group, 18 cases) and prednisone plus dipyridamole (control group, 17 cases), respectively. The clinical symptom and blood biochem. markers in therapeutic group were significantly ameliorated compared with those in control group (p<0.01). The levels of urine protein and blood lipid in therapeutic group were significantly lower than those in control group (p<0.05). - Data incomplete.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Egb761Type of experiment : in vivoType of animal : rabbitType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntravenousDose/Conc.(herb) : Egb761 40 mg/kg + dipyridamole 0.8 mg/kgDuration : -Type of interaction : PharmacodynamicsInteraction with drug : DipyridamoleDose/Conc.(drug) : -Result : PositiveRemark :Note : - 35 rabbits were divided randomly into 5 groups: Group A (sham group), Group B (model group), Group C (treated with dipyridamole 0.8 mg/kg), Group D (treated with Egb761, 40 mg/kg) and Group E (treated with Egb761 40 mg/kg combined with dipyridamole 0.8 mg/kg). - Results : Both Egb761 and dipyridamole could increase myocardial iNOS expression in transcriptive and translative levels in rabbits after myocardial ischemia-reperfusion injury, and the combined treatment of them shows a more significant effect. - Data incomplete.
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Case seriesN(Total) : 547N(Treatment) : *Sex : -Age : -Route : Non-specifiedDose/Conc.(herb) : -Duration : -Type of interaction : Non-specifiedInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark :Note : *Subject (N) treatment: Complementary and alternative medicine (CAM) was used in 77% of our population (421.19). - 599 CAM usages that could result in drug interactions. Data incomplete.
